デフォルト表紙
市場調査レポート
商品コード
1470514

臨床試験市場:デザイン、フェーズ、適応症別-世界予測2024-2030年

Clinical Trials Market by Design (Interventional Study, Observational Study), Phase (Phase I, Phase II, Phase III), Indication - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
臨床試験市場:デザイン、フェーズ、適応症別-世界予測2024-2030年
出版日: 2024年04月17日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

臨床試験市場規模は2023年に383億米ドルと推計され、2024年には417億8,000万米ドルに達し、CAGR 9.16%で2030年には707億8,000万米ドルに達すると予測されています。

臨床試験は、新しい検査や治療法を調査し、健康への影響を評価する研究活動です。薬物、細胞、その他の生物学的製品、外科的処置、放射線処置、装置、行動療法、予防医療を含む医療介入のテストに人々が参加することを可能にします。慢性疾患や感染症に関する懸念から、ジェネリック医薬品や生物学的製剤の開発・商業化が重視されるようになり、臨床試験の需要が高まっています。医薬品開発活動に重点が置かれるようになり、製薬・バイオテクノロジー業界の研究開発費が増加していることが、臨床試験の需要を高めています。しかし、臨床試験活動に関連する多額のコストや厳しい政府規制が、医薬品開発や研究活動を鈍らせています。企業は革新的な調査手法の提供とともにコスト削減に注力しています。さらに、医薬品開発への世界の注目と患者中心の臨床試験へのシフト、急速に改善する臨床試験の世界化、規制の調和と透明性の向上は、イノベーションと患者の健康と福祉の向上を促進します。

主な市場の統計
基準年[2023] 383億米ドル
予測年[2024] 417億8,000万米ドル
予測年 [2030] 707億8,000万米ドル
CAGR(%) 9.16%

デザイン治療の有効性、リスク、安全性の評価を最適化するための介入型臨床試験と観察型臨床試験のデザインの重要性

介入研究と観察研究は、医学的知識を深めるための異なる目的を持つ、KEYWORDにおける2つの異なる研究アプローチです。介入研究では、研究者が参加者を適応試験、非ランダム化比較試験、ランダム化比較試験などの特定の治療や介入に割り付け、健康結果に対する効果を評価します。さらに、観察研究では、研究者が被験者のケアを妨げることなく被験者を観察し、横断的活動、対照、生態学的調査などの曝露間の関連を調べる。介入研究は、その管理された設定により、より高いレベルのエビデンスを提供するが、費用がかかり、時間がかかり、倫理的に制限されることがあります。一方、観察研究は現実の状況を反映しているため、より一般化可能な結果が得られるが、管理されていない交絡因子によるバイアスがかかりやすいです。

フェーズ:薬物代謝をモニタリングし、初期データを収集するための臨床試験のフェーズ。

臨床試験は、新しい治療法、医薬品、機器の開発および承認に不可欠です。これらの臨床試験は、安全性、有効性、適切な用法・用量を確保するための様々なフェーズで構成され、規制されたプロセスに従って行われます。第Ⅱ相試験では、特定の病状の患者において、薬物や治療が治療効果をもたらすかどうかを判定することにより、有効性を評価します。第Ⅲ相試験(臨床試験)は、数百人から数千人までの多様な集団を対象に実施される大規模試験です。このフェーズでは、異なる環境や場所において、より広範な患者集団における治療の安全性と有効性を確認することを目的とします。第Ⅳ相試験(臨床試験)は、医薬品が規制当局によって承認され、上市された後に実施されます。これらの試験は、薬剤の副作用や新たな用途の可能性を評価し続けながら、より多くの集団における長期的な安全性と有効性をモニタリングすることを目的としています。

適応症:慢性疾患、心血管疾患、その他の有害な疾患に対する適切な治療法や薬剤を示唆するいくつかの適応症

臨床試験は、広く疾患や症状を示し、薬物療法、手順、治療について研究者を支援します。自己免疫の臨床試験は、慢性的で有害な炎症を伴う疾患についての参考資料となります。この研究は、自己免疫疾患や炎症性疾患の患者と健常人のバイオマーカーを同定することを目的としています。心血管系の痛みに関する臨床試験では、心房-心室(AV)および心室間(VV)のタイミングの遅れを調整することが、運動中の心臓の血行動態に及ぼす影響を明らかにします。中枢神経系の臨床試験では、脳炎や脊髄炎を含む様々な処置を受けた被験者の血清と脳脊髄液のサンプルをペアにして調べ、感染や炎症が疑われる特定の経路を調査しています。さらに、人間状態、糖尿病、腫瘍学に関わる臨床試験は、研究者が病気に対する患者の免疫系反応を理解し、病気の予防や治療法の改善に役立てる。

地域別インサイト

南北アメリカにおける臨床試験の拡大は、がん診断や心血管疾患に対するニーズの増加により著しく改善されました。米国食品医薬品局(FDA)や国家衛生監視局(ANVISA)など、多くの規制機関が医薬品開発の規制枠組みを確立し、実施される臨床試験の品質を保証しています。メキシコ、アルゼンチン、ブラジルのような新興諸国では、医療・ヘルスケアインフラの発展を後押しするため、研究開発や技術進歩を奨励するための多額の投資が政府によって行われています。アジア太平洋地域の臨床試験市場は、中国、インド、韓国、台湾、インドネシア、ベトナムなどの国々で製薬産業が発展しているため、急速に成長しています。近年、オーストラリアとニュージーランドでは、バイオテクノロジーと製薬産業への投資が増加しており、新興経済国のため臨床試験活動が大きく成長しています。欧州は、数多くの製薬会社やバイオテクノロジー企業が存在するため、世界の臨床試験の激戦地と考えられてきました。欧州連合(EU)には、治験薬の安全性、有効性、品質を保証するために、加盟国全体で臨床試験を実施するための確立された枠組みがあります。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは臨床試験市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、臨床試験市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1.臨床試験市場の市場規模および予測は?

2.臨床試験市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3.臨床試験市場の技術動向と規制枠組みは?

4.臨床試験市場における主要ベンダーの市場シェアは?

5.臨床試験市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • CRO統合による疾病罹患率の上昇と臨床試験の改善
      • 医薬品およびバイオ医薬品業界の研究開発費の増加
      • ジェネリック医薬品と生物製剤の開発と商業化への重点化
    • 抑制要因
      • 医薬品開発コストの増加と熟練した臨床調査専門家の不足
    • 機会
      • 医薬品開発への重点強化と患者中心への移行臨床試験
      • 臨床試験の世界化と規制の調和の進展
    • 課題
      • 患者登録に関する厳しい規制と国境を越えた物流の課題
  • 市場セグメンテーション分析
    • デザイン:治療の有効性、リスク、安全性の評価を最適化するための介入および観察臨床試験デザインの重要性
    • 段階:薬物代謝のモニタリングと初期データの収集のための臨床試験の段階的実施
    • 適応症:慢性疾患、心血管疾患、その他の有害な疾患に対する適切な治療法や投薬を示唆するいくつかの適応症
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 臨床試験市場:設計別

  • 介入研究
  • 観察研究

第7章 臨床試験市場フェーズ別

  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第8章 臨床試験市場適応症別

  • 自己免疫/炎症
  • 心臓血管
  • 中枢神経系の状態
  • 糖尿病
  • 感染症
  • 肥満
  • 腫瘍学
  • 疼痛管理

第9章 南北アメリカの臨床試験市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の臨床試験市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの臨床試験市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス、2023
  • 競合シナリオ分析
    • コールバーグがワールドワイドの過半数株式を取得臨床試験
    • アルカンザとレベレスが提携し、過小評価されているコミュニティにおける包括的な臨床調査を拡大
    • ブリストル・マイヤーズスクイブとヤンセンの共同研究が、経口因子XIa阻害剤ミルベキアンを評価する重要な第3相リブレキシア臨床試験プログラムを開始
  • 戦略分析と提言

第13章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CLINICAL TRIALS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL TRIALS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE CLINICAL TRIAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ADAPTIVE CLINICAL TRIAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIALS MARKET SIZE, BY NON-RANDOMIZED CONTROL TRIAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIALS MARKET SIZE, BY NON-RANDOMIZED CONTROL TRIAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED CONTROL TRIAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CLINICAL TRIALS MARKET SIZE, BY RANDOMIZED CONTROL TRIAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CASE CONTROL STUDY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CASE CONTROL STUDY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COHORT STUDY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COHORT STUDY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CROSS SECTIONAL STUDY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CROSS SECTIONAL STUDY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ECOLOGICAL STUDY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ECOLOGICAL STUDY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CLINICAL TRIALS MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CLINICAL TRIALS MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CNS CONDITION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CNS CONDITION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBESITY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OBESITY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL CLINICAL TRIALS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 315. GERMANY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. GERMANY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 325. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. ISRAEL CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 335. ITALY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 336. ITALY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 338. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 339. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 340. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 341. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 342. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 343. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 344. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 345. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 346. NETHERLANDS CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 347. NIGERIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 348. NIGERIA CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 349. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 350. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 351. NIGERIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 352. NIGERIA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDY, 2024-2030 (USD MILLION)
  • TABLE 353. NIGERIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 354. NIGERIA CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 355. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 356. NIGERIA CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 357. NORWAY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 358. NORWAY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 359. NORWAY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2018-2023 (USD MILLION)
  • TABLE 360. NORWAY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDY, 2024-2030 (U
目次
Product Code: MRR-434CCDA05152

[184 Pages Report] The Clinical Trials Market size was estimated at USD 38.30 billion in 2023 and expected to reach USD 41.78 billion in 2024, at a CAGR 9.16% to reach USD 70.78 billion by 2030.

Clinical trials are research activities that study new tests and treatments and evaluate effects on human health outcomes. It allows people to participate in testing medical interventions, including drugs, cells, other biological products, surgical procedures, radiological procedures, devices, behavioral treatments, and preventive care. The increased focus on developing and commercializing generics and biologics due to concerns related to chronic and infectious diseases increases demand for clinical trials. The growing emphasis on drug development activities and rising research and development expenditure from the pharmaceutical and biotechnology industry enhances the demand for clinical trials. However, the significant cost associated with clinical trial activities and stringent government regulations slow down drug development and research activities. Companies are focusing on cutting a cost alongside providing innovative research methodologies. Moreover, the worldwide focus on drug development and shift towards patient-centric clinical trials alongside rapidly improving globalization of clinical trials and greater regulatory harmonization and transparency promote innovation and better patient health and welfare.

KEY MARKET STATISTICS
Base Year [2023] USD 38.30 billion
Estimated Year [2024] USD 41.78 billion
Forecast Year [2030] USD 70.78 billion
CAGR (%) 9.16%

Design: Importance of interventional and observational clinical trial design to optimize assessment of treatment efficacy, risk, and safety

Interventional and observational studies are two distinct research approaches in clinical trials, serving different purposes in advancing medical knowledge. Interventional studies involve researchers assigning participants to specific treatments and interventions such as adaptive clinical trials, non-randomized control trials, and randomized control trials to assess their effects on health outcomes. Additionally, observational studies involve researchers observing subjects without interfering in their care to examine associations between exposures, including cross-sectional activities, control, and ecological study. Interventional studies provide higher levels of evidence due to their controlled settings but can be expensive, time-consuming, and ethically limited. On the other hand, observational studies offer more generalizable results since they reflect real-world conditions but are prone to biases from uncontrolled confounding factors.

Phase: clinical trial phases in for monitoring drug metabolism and gathering initial data

Clinical trials are essential in developing and approving new medical treatments, drugs, and devices. These trials follow a structured and regulated process with different phases ensuring safety, efficacy, and appropriate dosage. In Phase II, researchers evaluate effectiveness by determining whether or not the drug or treatment produces therapeutic benefits in patients with specific medical conditions. Phase III clinical trials are large-scale studies conducted on a diverse population ranging from several hundred to several thousand participants. This phase aims to confirm the safety and efficacy of a treatment in a broader patient population under different settings and locations. Phase IV clinical trials occur after a drug has been approved by regulatory authorities and released into the market. These trials aim to monitor long-term safety and effectiveness in a larger population while continuing to evaluate the drug's side effects and potential new uses.

Indication: Several indications suggesting suitable treatments and medications for chronic, cardiovascular, and other harmful diseases

Clinical trials widely indicate a disease or symptom and help researchers with medication, procedure, and treatment. Clinical trials of Autoimmune help learn more about conditions with chronic and harmful inflammation. This study aims to identify biomarkers in people with autoimmune or inflammatory diseases and healthy people. Clinical trial in cardiovascular pain helps to determine the results of adjusting atrial-ventricular (AV) and interventricular (VV) timing delays on cardiac hemodynamics during exercise. Clinical trials in CNS examine paired serum and cerebrospinal fluid samples from subjects with various procedures, including encephalitis and myelitis, to investigate specific pathways of suspected infection and inflammation. In addition, clinical trials involved in the human condition, diabetes, and oncology help researchers understand the patient's immune system response to a disease and work to prevent it and improve its treatment.

Regional Insights

The growing expansion of clinical trials in the Americas significantly improved due to the increasing need for cancer diagnostic and cardiovascular diseases. Many regulatory organizations, such as the United States Food and Drug Administration (FDA) and the National Health Surveillance Agency (ANVISA), establish regulatory frameworks for drug development to ensure the quality of clinical trials conducted. In developing countries such as Mexico, Argentina, and Brazil, governments are making considerable investments to encourage research and technological advancements to boost the development of medical & healthcare infrastructure. The Asia-Pacific region's clinical trial market is growing rapidly due to its evolving pharmaceutical industry in some countries, including China, India, South Korea, Taiwan, Indonesia, and Vietnam. In recent years, the growing investments in biotechnology and pharmaceutical industries in Australia and New Zealand have shown significant growth in clinical trial activities due to their emerging economies. Europe has been considered a rampart place for the global clinical trial due to the presence of numerous pharmaceutical and biotechnology companies. The European Union (EU) has a well-established framework for conducting clinical trials across its member states that ensures the safety, efficacy, and quality of investigational medicinal products.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Clinical Trials Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Clinical Trials Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include Accell Clinical Research, LLC, Atlant Clinical Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Charles River Laboratories International, Inc., Clinipace, Congenix LLP, Eli Lilly and Company, Icon PLC, Illumina, Inc, IQVIA Holdings, Inc., Labcorp, Merck KGaA, Novo Nordisk A/S, Parexel International Corporation, Pfizer Inc., ProPharma Group Holdings, LLC, Qiagen NV, Sartorius AG, SGS S.A., SIRO Clinpharm Private Limited, Syneos Health, Inc., Thermo Fisher Scientific Inc., and Wuxi AppTec Inc..

Market Segmentation & Coverage

This research report categorizes the Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Design
    • Interventional Study
      • Adaptive Clinical Trial
      • Non-randomized Control Trial
      • Randomized Control Trial
    • Observational Study
      • Case Control Study
      • Cohort Study
      • Cross Sectional Study
      • Ecological Study
  • Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Indication
    • Autoimmune/Inflammation
    • Cardiovascular
    • CNS condition
    • Diabetes
    • Infectious Diseases
    • Obesity
    • Oncology
    • Pain management
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Clinical Trials Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Clinical Trials Market?

3. What are the technology trends and regulatory frameworks in the Clinical Trials Market?

4. What is the market share of the leading vendors in the Clinical Trials Market?

5. Which modes and strategic moves are suitable for entering the Clinical Trials Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diseases and improved clinical trials due to CRO consolidation
      • 5.1.1.2. Growing R&D expenditure of pharmaceutical and biopharmaceutical industry
      • 5.1.1.3. Increased focus on the development and commercialization of generics and biologics
    • 5.1.2. Restraints
      • 5.1.2.1. Increased cost of drug development and lack of skilled clinical research professional
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased focus on drug development and shift towards patient-centric clinical trials
      • 5.1.3.2. Growing globalization of clinical trials and harmonization of regulations
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for patient enrollment and cross-border logistics challenges
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Design: Importance of interventional and observational clinical trial design to optimize assessment of treatment efficacy, risk, and safety
    • 5.2.2. Phase: clinical trial phases in for monitoring drug metabolism and gathering initial data
    • 5.2.3. Indication: Several indications suggesting suitable treatments and medications for chronic, cardiovascular, and other harmful diseases
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Clinical Trials Market, by Design

  • 6.1. Introduction
  • 6.2. Interventional Study
  • 6.3. Observational Study

7. Clinical Trials Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Clinical Trials Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune/Inflammation
  • 8.3. Cardiovascular
  • 8.4. CNS condition
  • 8.5. Diabetes
  • 8.6. Infectious Diseases
  • 8.7. Obesity
  • 8.8. Oncology
  • 8.9. Pain management

9. Americas Clinical Trials Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Kohlberg Acquires Majority Stake in Worldwide Clinical Trials
    • 12.3.2. Alcanza and Reveles Partner to Expand Inclusive Clinical Research in Underrepresented Communities
    • 12.3.3. The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio